Alnylam Pharmaceuticals (ALNY) Price Target Cut to $118.00 by Analysts at Morgan Stanley

Alnylam Pharmaceuticals (ALNY) Price Target Cut to $118.00 by Analysts at Morgan Stanley


The firm currently has an "equal weight" rating on the biopharmaceutical company's stock. Morgan Stanley's price objective indicates a potential upside of 1.79% from the company's current price.



from Biotech News